The Indian government has decided to cap trade margins on all non-scheduled anti-cancer drugs at 30 per cent of their maximum retail price. This move aims to improve affordability and ensure continued availability of these life-saving medicines, potentially saving cancer patients an estimated Rs 2,500 crore annually. The decision, expected to be implemented later this month, will affect 110 anti-cancer drugs, including 35 patented ones.